logo
Plus   Neg
Share
Email

Sandoz's Data Shows Effectiveness Of Erelzi In Rheumatic Disease Treatment

Sandoz, a Novartis division, presented real-world data showing effectiveness of Erelzi in rheumatic disease treatment.

Patients with rheumatoid arthritis (RA), active and progressive psoriatic arthritis (PsA) and ankylosing spondylitis (AS) were included in the COMPACT study, the company said.

In addition to the COMPACT analysis, Sandoz presented results from a US economic model. Investigators evaluated the economic impact of switching patients from a reference etanercept to a biosimilar in patients with rheumatic diseases in the US, taking into consideration the upfront costs when implementing a formulary change.

Sandoz said the results demonstrated that despite the early, administrative costs associated with managing the formulary process, substantial cost savings can be realized by integrated delivery networks (IDNs) when transitioning patients to the biosimilar.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The European Commission said Friday that it has signed a deal with Sanofi and GlaxoSmithKline to secure up to 300 million doses of their potential COVID-19 vaccine. Acella Pharmaceuticals recalled certain lots of hypothyroidism medication NP Thyroid in the form of tablets due to super potency, the U.S. Food and Drug Administration said in a statement. The company is recalling one lot of 15mg and one lot of 120mg of NP Thyroid that are packaged in 100 count bottles in strengths of 15 mg, and 120 mg, with expiration dates between October 2020 and November 2020. Walmart announced its decision to raise wages for around 165,000 hourly associates across all its U.S. stores starting October, and introduce a team-based operating model in Supercenters. In a tweet, the retail giant said, "Today we're introducing new leadership roles and cross-training opportunities, giving our associates more ways to grow their careers."
Follow RTT